Neogen (NEOG)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
$11.68-6.26%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · NEOG
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 43.9% |
| Our one-year growth estimate | diamond | -2.2% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 46.1 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 43 industry peers · Company calendar date is not available
NEOG — divestiture
Dated 2026-11-04
Other Events. On March 2, 2026, Neogen Corporation (“ Neogen ”) announced that it had entered into a definitive agreement to sell its global Genomics business to Zoetis Inc. (“ Zoetis ”). This transaction is subject to customary closing conditions and regulatory approvals. Both parties continue to cooperate with the Australian Competition and Consumer Commission (the “ ACCC ”) and the New Zealand Commerce Commission (the “ NZCC”) in their ongoing reviews of the transaction. In order to assist…
Why it matters: Neogen plans to use most sale proceeds to cut debt. Delays or a failed deal would change that plan.
Watch forThe Zoetis sale closes by December 2026, after regulatory reviews. Proceeds are near the stated $160 million price.
Also watch forThe deal does not close by December, regulators block it, or Neogen reports a lower sale price.
Why it matters: The raised range rests on continued growth after a strong first quarter. Falling short would weaken that growth signal.
Watch forNeogen keeps FY27 revenue guidance at $885–$890 million or raises it again.
Also watch forNeogen cuts FY27 revenue guidance below $885 million, or reports results that put the range out of reach.
Why it matters: Food Safety is Neogen's largest segment. Growth in this business can offset weakness elsewhere.
Supportive ifFood Safety core revenue growth stays above 5% in the next reported quarter.
Worry ifFood Safety core revenue growth falls to 0% or less in the next reported quarter.
Why it matters: Neogen plans to start moving Petrifilm production to Lansing in November. Smooth output would support supply and service.
Supportive ifNeogen starts the shift in November and makes saleable product at Lansing. It reports no major quality or supply issues.
Worry ifThe start slips past November, or Neogen reports failed tests, product shortages, or major delays.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$145 on $10,000 · ±1.5% | How much price usually moves either way. |
| Bad day | $450 loss on $10,000 · 4.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,771 loss on $10,000 · 27.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.